The primary goal of the CETR Administrative Core (Core A) is to promote success for all CETR programs including research programs and cores, supplemental research projects, financial monitoring and oversight, compliance and regulatory activities, biosafety and security issues, for all personnel, materials, data and facilities associated with CCTRHIB programs. The Core will work closely with the Scientific Advisory Board to assure that excellent progress is made on all projects, and that innovative supplemental projects are being funded. The Administrative Core is ultimately responsible for ensuring that the mission of this CETR for novel vaccine technology platform for high medical need infectious is met. Under Dr. Jenny Ting, Program Director and Dr. Barbara Vilen, Associate Director, the Administrative Core supports the scientific and translational goals as follows: (1) Execute day-to-day operations and management, including monitoring of expenditures, addressing grant management issues as well as unexpected issues that arise. (2) Managing, coordinating, and supervising Scientific Projects 1-3 and Cores B-D. (3) Coordinate the review activities ofthe advisory committee, both reviews of Projects and Cores and reviews of supplemental applications. (4) Oversee activities of the research programs, core activities, supplemental research projects to assure proper compliance and regulatory activities, biosafety and security issues for all personnel, materials, data publication and resource sharing, and technology transfer/intellectual properties necessary for product development associated with Center programs.

Public Health Relevance

The Administrative Core is ultimately responsible for ensuring the successful completion of the Center's mission to advance medical countermeasures to Emerging and Re-emerging Infectious Diseases. The Scientific Administrators, the Administrative Staff and Regulatory personnel will work together toward that goal. The Administrative Core is ultimately responsible for ensuring the successful completion of the Center's mission to advance medical countermeasures to Emerging and Re-emerging Infectious Diseases. The Scientific Administrators, the Administrative Staff and Regulatory personnel will work together toward that goal.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI109784-01
Application #
8657215
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Collier, Michael A; Junkins, Robert D; Gallovic, Matthew D et al. (2018) Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists. Mol Pharm 15:4933-4946
Cheng, Ning; Watkins-Schulz, Rebekah; Junkins, Robert D et al. (2018) A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer. JCI Insight 3:
Chen, Naihan; Johnson, Monica M; Collier, Michael A et al. (2018) Tunable degradation of acetalated dextran microparticles enables controlled vaccine adjuvant and antigen delivery to modulate adaptive immune responses. J Control Release 273:147-159
Metz, Stefan W; Thomas, Ashlie; White, Laura et al. (2018) Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope. Virol J 15:60
Shao, Wenwei; Earley, Lauriel F; Chai, Zheng et al. (2018) Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction. JCI Insight 3:
Junkins, Robert D; Gallovic, Matthew D; Johnson, Brandon M et al. (2018) A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination. J Control Release 270:1-13
Cheng, Liang; Wang, Qi; Li, Guangming et al. (2018) TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs. J Clin Invest 128:4387-4396
Metz, Stefan W; Thomas, Ashlie; Brackbill, Alex et al. (2018) Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype. PLoS Negl Trop Dis 12:e0006793
Chen, Naihan; Gallovic, Matthew D; Tiet, Pamela et al. (2018) Investigation of tunable acetalated dextran microparticle platform to optimize M2e-based influenza vaccine efficacy. J Control Release 289:114-124
Swanson, Karen V; Junkins, Robert D; Kurkjian, Cathryn J et al. (2017) A noncanonical function of cGAMP in inflammasome priming and activation. J Exp Med 214:3611-3626

Showing the most recent 10 out of 23 publications